Novartis AG(NVS)Earnings, Financials & Key Ratios
NVS•NYSE
20.5× P/E·Price updated Jun 19, 2026
AboutNovartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.Show more
- Revenue$54.81B+6.0%
- EBITDA$22.43B+8.8%
- Net Income$14.06B+17.7%
- EPS (Diluted)7.19+22.5%
- Gross Margin75.02%-0.2%
- EBITDA Margin40.92%+2.7%
- Operating Margin31.15%+10.8%
- Net Margin25.64%+11.1%
- ROE31%+18.0%
NVS Key Insights
Novartis AG (NVS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 28.4%
- ✓FCF machine: 32.3% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Healthy dividend yield of 2.7%
- ✓Share count reduced 3.9% through buybacks
- ✓Healthy 5Y average net margin of 30.2%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when NVS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NVS Price & Volume
Novartis AG (NVS) stock price & volume — 10-year historical chart
Loading chart...
NVS Growth Metrics
Novartis AG (NVS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years0.85%
5 Years1.9%
3 Years8.04%
TTM5.32%
Profit CAGR
10 Years-2.32%
5 Years11.73%
3 Years26.43%
TTM5.25%
EPS CAGR
10 Years-0.14%
5 Years15.36%
3 Years31.39%
TTM9.23%
Return on Capital
10 Years11.39%
5 Years14.25%
3 Years17.64%
Last Year21.1%
NVS Recent Earnings
Novartis AG (NVS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
Apr 28, 2026Metric
Actual
Est
EPS
$1.99-5.7%
$2.11
Rev
$13.1B-2.4%
$13.4B
Q1 2026
Feb 4, 2026Metric
Actual
Est
EPS
$2.03+2.0%
$1.99
Rev
$13.3B-2.7%
$13.7B
Q4 2025
Oct 28, 2025Metric
Actual
Est
EPS
$2.25-0.4%
$2.26
Rev
$14.4B+5.3%
$13.6B
Q3 2025
Jul 17, 2025Metric
Actual
Est
EPS
$2.42+1.7%
$2.38
Rev
$14.3B+2.5%
$13.9B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 28, 2026 | $1.99vs $2.11-5.7% | $13.1Bvs $13.4B-2.4% |
| Q1 2026 | Feb 4, 2026 | $2.03vs $1.99+2.0% | $13.3Bvs $13.7B-2.7% |
| Q4 2025 | Oct 28, 2025 | $2.25vs $2.26-0.4% | $14.4Bvs $13.6B+5.3% |
| Q3 2025 | Jul 17, 2025 | $2.42vs $2.38+1.7% | $14.3Bvs $13.9B+2.5% |
Based on last 12 quarters of dataView full earnings history →
NVS Peer Comparison
Novartis AG (NVS) competitors in Generics and biosimilars manufacturers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PFE | 143.46B | 25.22 | 18.54 | -1.65% | 11.83% | 8.34% | 0.78 | |
 AZN | 271.19B | 174.93 | 26.75 | 8.63% | 17.19% | 22.24% | 0.61 | |
 NVO | 191.93B | 43.19 | 12.18 | 6.43% | 37.2% | 66.36% | 0.67 | |
 SNY | 102.35B | 42.38 | 18.14 | 5.49% | 16.72% | 10.78% | 0.30 | |
 GSK | 101.9B | 50.67 | 6.86 | 4.11% | 19.19% | 31.48% | 1.11 | |
 MRK | 281.25B | 113.87 | 15.64 | 1.18% | 28.12% | 36.14% | 0.96 | |
 LLY | 1.04T | 1098.13 | 47.85 | 44.7% | 34.98% | 101.17% | 1.60 | |
 ABT | 153.68B | 88.38 | 11.57 | 4.59% | 31.88% | 27.26% | 0.32 |
Compare NVS vs Peers
Novartis AG (NVS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NVS Income Statement
Novartis AG (NVS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 43.4B | 46.1B | 48.68B | 49.9B | 43.97B | 43.46B | 46.66B | 51.72B | 54.81B | 56.05B |
Revenue Growth % | -12.2% | 6.21% | 5.59% | 2.51% | -11.87% | -1.17% | 7.36% | 10.85% | 5.97% | 5.32% |
Cost of Goods Sold | 13.63B | 14.51B | 14.43B | 15.12B | 11.73B | 11.58B | 12.47B | 12.83B | 13.69B | 13.86B |
COGS % of Revenue | 31.41% | 31.48% | 29.63% | 30.3% | 26.69% | 26.65% | 26.73% | 24.8% | 24.98% | - |
Gross Profit | 29.77B▲ 0% | 31.59B▲ 6.1% | 34.25B▲ 8.4% | 34.78B▲ 1.5% | 32.24B▼ 7.3% | 31.88B▼ 1.1% | 34.19B▲ 7.2% | 38.9B▲ 13.8% | 41.12B▲ 5.7% | 42.19B▲ 0% |
Gross Margin % | 68.59% | 68.52% | 70.37% | 69.7% | 73.31% | 73.35% | 73.27% | 75.2% | 75.02% | 75.27% |
Gross Profit Growth % | -6.72% | 6.11% | 8.43% | 1.53% | -7.3% | -1.12% | 7.24% | 13.77% | 5.72% | - |
Operating Expenses | 21.07B | 23.19B | 25.17B | 24.63B | 22.18B | 23.93B | 24.42B | 24.35B | 24.05B | 25.07B |
OpEx % of Revenue | 48.54% | 50.3% | 51.7% | 49.35% | 50.45% | 55.07% | 52.33% | 47.08% | 43.87% | - |
Selling, General & Admin | 12.46B | 13.72B | 14.37B | 14.2B | 12.83B | 12.19B | 12.52B | 12.57B | 13.31B | 13.33B |
SG&A % of Revenue | 28.72% | 29.76% | 29.52% | 28.45% | 29.17% | 28.06% | 26.83% | 24.3% | 24.28% | - |
Research & Development | 8.39B | 8.49B | 9.4B | 8.98B | 8.64B | 9.17B | 11.37B | 10.02B | 10.74B | 11.25B |
R&D % of Revenue | 19.33% | 18.41% | 19.32% | 18% | 19.65% | 21.1% | 24.37% | 19.38% | 19.6% | - |
Other Operating Expenses | 215M | 980M | 1.4B | 1.45B | 715M | 2.57B | 531M | 1.76B | 0 | 1000K |
Operating Income | 8.7B▲ 0% | 8.4B▼ 3.4% | 9.09B▲ 8.1% | 10.15B▲ 11.7% | 10.06B▼ 0.9% | 7.95B▼ 21.0% | 9.77B▲ 22.9% | 14.54B▲ 48.9% | 17.07B▲ 17.4% | 17.12B▲ 0% |
Operating Margin % | 20.05% | 18.23% | 18.67% | 20.35% | 22.87% | 18.28% | 20.94% | 28.12% | 31.15% | 30.54% |
Operating Income Growth % | 5.25% | -3.44% | 8.13% | 11.73% | -0.95% | -20.98% | 22.94% | 48.88% | 17.4% | - |
EBITDA | 13.44B | 13.61B | 14.91B | 16.62B | 15.65B | 14.65B | 18.05B | 20.61B | 22.43B | 22.52B |
EBITDA Margin % | 30.96% | 29.53% | 30.63% | 33.3% | 35.6% | 33.71% | 38.68% | 39.85% | 40.92% | 40.18% |
EBITDA Growth % | -6.1% | 1.31% | 9.53% | 11.43% | -5.8% | -6.4% | 23.17% | 14.22% | 8.8% | 3.57% |
D&A (Non-Cash Add-back) | 4.74B | 5.21B | 5.83B | 6.46B | 5.6B | 6.71B | 8.28B | 6.07B | 5.35B | 5.4B |
EBIT | 9.85B | 15.03B | 9.79B | 10.75B | 25.32B | 7.98B | 9.98B | 14.65B | 17.63B | 17B |
Net Interest Income | -692M | -680.55M | -657.67M | -830M | -834M | -456.89M | -246.88M | -468.74M | -812.14M | -1.22B |
Interest Income | 110M | 292.67M | 245.25M | 91M | 71M | 377.74M | 629.24M | 567.68M | 374.91M | 0 |
Interest Expense | 802M | 973.22M | 902.93M | 921M | 905M | 834.62M | 876.12M | 1.04B | 1.19B | 1.22B |
Other Income/Expense | 400M | 5.69B | -146M | -274M | 14.47B | -769M | -646M | -904M | -638.25M | -1.34B |
Pretax Income | 9.1B▲ 0% | 14.1B▲ 54.9% | 8.94B▼ 36.6% | 9.88B▲ 10.5% | 24.53B▲ 148.3% | 7.18B▼ 70.7% | 9.12B▲ 27.1% | 13.64B▲ 49.5% | 16.44B▲ 20.5% | 15.78B▲ 0% |
Pretax Margin % | 20.97% | 30.58% | 18.37% | 19.8% | 55.78% | 16.51% | 19.55% | 26.37% | 29.99% | 28.16% |
Income Tax | 1.6B | 1.29B | 1.79B | 1.81B | 1.63B | 1.13B | 551M | 1.7B | 2.4B | 2.27B |
Effective Tax Rate % | 17.61% | 9.19% | 20.06% | 18.29% | 6.62% | 15.72% | 6.04% | 12.47% | 14.59% | 14.38% |
Net Income | 7.7B▲ 0% | 12.61B▲ 63.7% | 11.73B▼ 7.0% | 8.07B▼ 31.2% | 24.02B▲ 197.6% | 6.96B▼ 71.0% | 14.85B▲ 113.5% | 11.94B▼ 19.6% | 14.06B▲ 17.7% | 13.53B▲ 0% |
Net Margin % | 17.75% | 27.36% | 24.1% | 16.18% | 54.63% | 16% | 31.83% | 23.09% | 25.64% | 24.14% |
Net Income Growth % | 14.76% | 63.72% | -6.97% | -31.2% | 197.58% | -71.05% | 113.52% | -19.59% | 17.71% | 5.25% |
Net Income (Continuing) | 7.5B | 12.8B | 7.15B | 8.07B | 22.91B | 6.05B | 8.57B | 11.94B | 14.04B | 13.51B |
Discontinued Operations | 0 | 0 | 0 | 0 | 1.11B | 906M | 6.28B | 0 | 0 | 0 |
Minority Interest | 59M | 78M | 77M | 68M | 167M | 81M | 83M | 80M | 419M | 415M |
EPS (Diluted) | 3.25▲ 0% | 5.38▲ 65.5% | 3.08▼ 42.8% | 3.52▲ 14.3% | 10.63▲ 202.0% | 3.17▼ 70.2% | 7.10▲ 124.0% | 5.87▼ 17.3% | 7.19▲ 22.5% | 7.06▲ 0% |
EPS Growth % | 16.07% | 65.54% | -42.75% | 14.29% | 201.99% | -70.18% | 123.97% | -17.32% | 22.49% | 9.23% |
EPS (Basic) | 3.28 | 5.44 | 3.12 | 3.54 | 10.71 | 3.19 | 7.15 | 5.92 | 7.25 | - |
Diluted Shares Outstanding | 2.37B | 2.34B | 2.32B | 2.3B | 2.26B | 2.2B | 2.09B | 2.04B | 1.96B | 1.92B |
Basic Shares Outstanding | 2.35B | 2.32B | 2.29B | 2.28B | 2.24B | 2.18B | 2.08B | 2.02B | 1.94B | 1.91B |
Dividend Payout Ratio | 84.32% | 55.24% | 56.64% | 86.56% | 30.67% | 107.92% | 48.86% | 63.85% | 55.91% | - |
NVS Balance Sheet
Novartis AG (NVS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 28.21B | 35.56B | 29.5B | 29.67B | 45.72B | 36.91B | 30.48B | 29.7B | 30.46B | 26.61B |
Cash & Short-Term Investments | 9.48B | 15.96B | 11.45B | 11.56B | 28.11B | 18.61B | 13.96B | 13.35B | 11.59B | 6.98B |
Cash Only | 8.86B | 13.27B | 11.11B | 9.66B | 12.41B | 7.52B | 13.39B | 11.46B | 11.44B | 6.88B |
Short-Term Investments | 625M | 2.69B | 334M | 1.91B | 15.71B | 11.1B | 569M | 1.89B | 155M | 100M |
Accounts Receivable | 10.07B | 9.68B | 9.17B | 9.07B | 9.62B | 9.89B | 9.38B | 8.21B | 10.93B | 9.6B |
Days Sales Outstanding | 84.68 | 76.61 | 68.78 | 66.37 | 79.86 | 83.09 | 73.34 | 57.94 | 72.81 | 62.99 |
Inventory | 6.87B | 6.96B | 5.98B | 7.13B | 6.67B | 7.17B | 5.91B | 5.72B | 6.27B | 6.29B |
Days Inventory Outstanding | 183.85 | 174.98 | 151.36 | 172.13 | 207.34 | 226.12 | 173.05 | 162.85 | 167.15 | 166.43 |
Other Current Assets | 1.03B | 3.23B | 2.01B | 963M | 216M | 315M | 466M | 1.43B | 514M | 3.74B |
Total Non-Current Assets | 104.87B | 110B | 88.91B | 102.52B | 86.08B | 80.54B | 69.46B | 72.54B | 85.11B | 91.92B |
Property, Plant & Equipment | 16.46B | 15.7B | 13.75B | 13.94B | 13.11B | 12.2B | 10.92B | 10.87B | 12.35B | 12.24B |
Fixed Asset Turnover | 2.64x | 2.94x | 3.54x | 3.58x | 3.36x | 3.56x | 4.27x | 4.76x | 4.44x | 4.63x |
Goodwill | 31.75B | 35.29B | 26.52B | 30B | 29.59B | 29.3B | 23.34B | 24.76B | 25.57B | 26.82B |
Intangible Assets | 30B | 38.72B | 28.79B | 36.81B | 34.18B | 31.64B | 26.88B | 26.91B | 29.41B | 40.21B |
Long-Term Investments | 17.61B | 10.7B | 11B | 12.44B | 2.27B | 1.61B | 1.83B | 1.13B | 2.3B | 9.05B |
Other Non-Current Assets | 818M | 895M | 897M | 981M | 3.18B | 2.06B | 2.18B | 4.51B | 5.42B | 4.98B |
Total Assets | 133.08B▲ 0% | 145.56B▲ 9.4% | 118.41B▼ 18.7% | 132.19B▲ 11.6% | 131.79B▼ 0.3% | 117.45B▼ 10.9% | 99.94B▼ 14.9% | 102.25B▲ 2.3% | 115.57B▲ 13.0% | 118.53B▲ 0% |
Asset Turnover | 0.33x | 0.32x | 0.41x | 0.38x | 0.33x | 0.37x | 0.47x | 0.51x | 0.47x | 0.50x |
Asset Growth % | 2.27% | 9.38% | -18.65% | 11.63% | -0.3% | -10.88% | -14.91% | 2.3% | 13.03% | 42.34% |
Total Current Liabilities | 23.4B | 29.61B | 28.26B | 33.06B | 30.21B | 28.66B | 26.39B | 28.69B | 27.28B | 31.37B |
Accounts Payable | 5.17B | 5.56B | 5.42B | 5.4B | 5.55B | 5.15B | 4.93B | 4.57B | 4.46B | 4.32B |
Days Payables Outstanding | 138.39 | 139.76 | 137.24 | 130.42 | 172.72 | 162.17 | 144.16 | 130.1 | 118.81 | 117.43 |
Short-Term Debt | 5.2B | 9.62B | 7.09B | 9.88B | 6.23B | 5.88B | 6.08B | 8.09B | 5.78B | 7.62B |
Deferred Revenue (Current) | 305M | 236M | 114M | 56M | 123M | 123M | 98M | 127M | 0 | 0 |
Other Current Liabilities | 8.68B | 9.63B | 10.98B | 12.98B | 12.44B | 11.21B | 9.84B | 10.38B | 12.82B | 17.36B |
Current Ratio | 1.21x | 1.20x | 1.04x | 0.90x | 1.51x | 1.29x | 1.16x | 1.04x | 1.12x | 0.85x |
Quick Ratio | 0.91x | 0.97x | 0.83x | 0.68x | 1.29x | 1.04x | 0.93x | 0.84x | 0.89x | 0.65x |
Cash Conversion Cycle | 130.14 | 111.83 | 82.89 | 108.08 | 114.48 | 147.04 | 102.23 | 90.7 | 121.15 | 112 |
Total Non-Current Liabilities | 35.45B | 37.26B | 34.6B | 42.46B | 33.77B | 29.37B | 26.8B | 29.43B | 41.74B | 48.23B |
Long-Term Debt | 23.22B | 22.47B | 20.35B | 26.26B | 22.9B | 20.24B | 18.44B | 21.37B | 29.59B | 37.45B |
Capital Lease Obligations | 0 | 0 | 1.7B | 1.72B | 1.62B | 1.54B | 1.6B | 1.57B | 1.66B | 6.55B |
Deferred Tax Liabilities | 5.17B | 7.47B | 5.91B | 7.55B | 3.07B | 2.69B | 2.25B | 2.42B | 8.02B | 17.61B |
Other Non-Current Liabilities | 6.55B | 8.85B | 6.63B | 6.93B | 6.17B | 4.91B | 4.52B | 4.08B | 2.48B | 4.02B |
Total Liabilities | 58.85B | 66.87B | 62.86B | 75.52B | 63.97B | 58.03B | 53.2B | 58.12B | 69.02B | 79.61B |
Total Debt | 28.43B | 32.09B | 29.15B | 37.85B | 31.02B | 27.91B | 26.35B | 31.26B | 37.03B | 47B |
Net Debt | 19.57B | 18.82B | 18.04B | 28.2B | 18.62B | 20.39B | 12.96B | 19.8B | 25.6B | 40.12B |
Debt / Equity | 0.38x | 0.41x | 0.52x | 0.67x | 0.46x | 0.47x | 0.56x | 0.71x | 0.80x | 1.21x |
Debt / EBITDA | 2.12x | 2.36x | 1.95x | 2.28x | 1.98x | 1.90x | 1.46x | 1.52x | 1.65x | 2.09x |
Net Debt / EBITDA | 1.46x | 1.38x | 1.21x | 1.70x | 1.19x | 1.39x | 0.72x | 0.96x | 1.14x | 1.78x |
Interest Coverage | 12.28x | 15.44x | 10.84x | 11.67x | 27.97x | 9.56x | 11.39x | 14.13x | 14.86x | 13.92x |
Total Equity | 74.23B▲ 0% | 78.69B▲ 6.0% | 55.55B▼ 29.4% | 56.67B▲ 2.0% | 67.82B▲ 19.7% | 59.42B▼ 12.4% | 46.75B▼ 21.3% | 44.13B▼ 5.6% | 46.55B▲ 5.5% | 38.93B▲ 0% |
Equity Growth % | -0.89% | 6.02% | -29.41% | 2.01% | 19.69% | -12.38% | -21.33% | -5.61% | 5.49% | 10.11% |
Book Value per Share | 31.31 | 33.57 | 23.95 | 24.68 | 30.01 | 27.05 | 22.35 | 21.68 | 23.81 | 20.32 |
Total Shareholders' Equity | 74.17B | 78.61B | 55.47B | 56.6B | 67.66B | 59.34B | 46.67B | 44.05B | 46.13B | 38.51B |
Common Stock | 969M | 944M | 936M | 913M | 901M | 890M | 825M | 793M | 766M | 736M |
Retained Earnings | 77.64B | 82.19B | 59.27B | 57.16B | 70.99B | 63.54B | 49.65B | 46.56B | 44.72B | 37.25B |
Treasury Stock | -100M | -69M | -80M | -53M | -48M | -92M | -41M | -53M | -50M | -47M |
Accumulated OCI | 73.3B | 77.74B | -4.66B | -1.42B | -4.19B | -5B | -3.77B | -3.25B | 694M | 571M |
Minority Interest | 59M | 78M | 77M | 68M | 167M | 81M | 83M | 80M | 419M | 415M |
NVS Cash Flow Statement
Novartis AG (NVS) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 12.62B | 14.27B | 13.63B | 13.65B | 15.07B | 14.24B | 14.46B | 17.62B | 19.24B | 19.16B |
Operating CF Margin % | 29.08% | 30.96% | 27.99% | 27.36% | 34.27% | 32.76% | 30.99% | 34.06% | 35.11% | - |
Operating CF Growth % | 9.99% | 13.08% | -4.53% | 0.18% | 10.41% | -5.54% | 1.56% | 21.86% | 9.21% | -4.17% |
Net Income | 7.7B | 12.61B | 7.15B | 8.07B | 22.91B | 6.05B | 8.57B | 11.94B | 14.06B | 13.53B |
Depreciation & Amortization | 6.08B | 6.89B | 5.83B | 6.46B | 5.6B | 6.71B | 8.28B | 6.07B | 5.35B | 5.4B |
Stock-Based Compensation | 683M | 759M | 758M | 738M | 700M | 791M | 865M | 1.04B | 0 | 838M |
Deferred Taxes | 1.3B | 1.22B | 1.79B | 1.81B | 1.63B | 1.13B | 551M | 1.7B | -361.84M | 1.46B |
Other Non-Cash Items | -3.38B | -7.71B | -2.1B | -3.14B | -15.68B | 359M | -3.44B | -2.43B | 3.27B | -745.32M |
Working Capital Changes | 244M | 499M | 199M | -291M | -73M | -796M | -369M | -706M | -3.08B | -1.3B |
Change in Receivables | -204M | -569M | -980M | 137M | -352M | -397M | -1.5B | -931M | -1.13B | -584.15M |
Change in Inventory | -247M | -533M | -382M | -543M | -102M | -560M | -546M | -225M | 34.17M | -115.08M |
Change in Payables | 58M | 309M | 553M | -324M | -111M | -181M | 479M | -105M | -274.4M | -152.99M |
Cash from Investing | -3.12B | -5.59B | -2.23B | -13.18B | 4.21B | 1.47B | 5.6B | -7.51B | -4.9B | -16.95B |
Capital Expenditures | -2.75B | -3.35B | -1.38B | -2.58B | -1.07B | -916M | -1.06B | -1.37B | -3.92B | -2.05B |
CapEx % of Revenue | 6.33% | 7.28% | 2.83% | 5.18% | 2.42% | 2.11% | 2.27% | 2.64% | 7.15% | 3.65% |
Acquisitions | -755M | -1.07B | -3.77B | -9.96B | 20.46B | -864M | -3.57B | -3.83B | -3.01B | -15.05B |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 551M | 895M | -264M | 282M | -1.34B | -1.43B | -624M | -2.38B | 140.72M | -1.02B |
Cash from Financing | -7.73B | -4.24B | -13.63B | -2.21B | -16.26B | -20.56B | -14.28B | -11.74B | -14.94B | -2.71B |
Debt Issued (Net) | 4.1B | 4.18B | -4.96B | 7.07B | -5.67B | -2.58B | -1.94B | 4.39B | 2.72B | 14.62B |
Equity Issued (Net) | -5.49B | -2.04B | -5.53B | -2.84B | -3.06B | -10.65B | -8.72B | -8.33B | -9.23B | -8.36B |
Dividends Paid | -6.5B | -6.97B | -6.64B | -6.99B | -7.37B | -7.51B | -7.25B | -7.62B | -7.86B | -8.64B |
Share Repurchases | -5.49B | -2.04B | -5.53B | -2.84B | -3.06B | -10.65B | -8.72B | -8.33B | -9.26B | -8.37B |
Other Financing | 151M | 581M | 3.51B | 549M | -169M | 181M | 3.63B | -177M | -577.95M | -320.31M |
Net Change in Cash | 1.85B▲ 0% | 4.41B▲ 138.0% | -2.16B▼ 148.9% | -1.45B▲ 32.7% | 2.75B▲ 289.1% | -4.89B▼ 277.9% | 5.88B▲ 220.2% | -1.93B▼ 132.9% | -24M▲ 98.8% | -188.95M▲ 0% |
Free Cash Flow | 9.88B▲ 0% | 10.92B▲ 10.6% | 11.37B▲ 4.1% | 11.06B▼ 2.7% | 12.52B▲ 13.1% | 12B▼ 4.1% | 11.71B▼ 2.4% | 13.8B▲ 17.9% | 17.69B▲ 28.1% | 16.36B▲ 0% |
FCF Margin % | 22.75% | 23.68% | 23.35% | 22.18% | 28.46% | 27.6% | 25.09% | 26.69% | 32.27% | 29.18% |
FCF Growth % | 14.88% | 10.55% | 4.13% | -2.67% | 13.1% | -4.14% | -2.43% | 17.94% | 28.11% | 10.18% |
FCF per Share | 4.16 | 4.66 | 4.90 | 4.82 | 5.54 | 5.46 | 5.60 | 6.78 | 9.05 | 8.54 |
FCF Conversion (FCF/Net Income) | 1.64x | 1.13x | 1.16x | 1.69x | 0.63x | 2.05x | 0.97x | 1.48x | 1.37x | 1.21x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NVS Key Ratios
Novartis AG (NVS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 10.33% | 16.49% | 17.48% | 14.39% | 38.59% | 10.93% | 27.97% | 26.28% | 31% | 31.42% |
Return on Invested Capital (ROIC) | 7.04% | 6.59% | 7.97% | 9.61% | 8.81% | 7.17% | 10.5% | 17.65% | 18.82% | 17.93% |
Gross Margin | 68.59% | 68.52% | 70.37% | 69.7% | 73.31% | 73.35% | 73.27% | 75.2% | 75.02% | 75.27% |
Net Margin | 17.75% | 27.36% | 24.1% | 16.18% | 54.63% | 16% | 31.83% | 23.09% | 25.64% | 24.14% |
Debt / Equity | 0.38x | 0.41x | 0.52x | 0.67x | 0.46x | 0.47x | 0.56x | 0.71x | 0.80x | 1.21x |
Interest Coverage | 12.28x | 15.44x | 10.84x | 11.67x | 27.97x | 9.56x | 11.39x | 14.13x | 14.86x | 13.92x |
FCF Conversion | 1.64x | 1.13x | 1.16x | 1.69x | 0.63x | 2.05x | 0.97x | 1.48x | 1.37x | 1.21x |
Revenue Growth | -12.2% | 6.21% | 5.59% | 2.51% | -11.87% | -1.17% | 7.36% | 10.85% | 5.97% | 5.32% |
Related:NVS Dividend History·NVS Revenue History·NVS Price History·NVS P/E History·NVS Financial Ratios·NVS Institutional Holders
NVS Frequently Asked Questions
Novartis AG (NVS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Novartis AG (NVS) reported $56.05B in revenue for fiscal year 2025. This represents a 143% increase from $23.04B in 1998.
Novartis AG (NVS) grew revenue by 6.0% over the past year. This is steady growth.
Yes, Novartis AG (NVS) is profitable, generating $13.53B in net income for fiscal year 2025 (25.6% net margin).
Dividend & Returns
Yes, Novartis AG (NVS) pays a dividend with a yield of 2.73%. This makes it attractive for income-focused investors.
Novartis AG (NVS) has a return on equity (ROE) of 31.0%. This is excellent, indicating efficient use of shareholder capital.
Novartis AG (NVS) generated $16.36B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.